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Abstract
Background: Farnesoid X receptor/retinoid X receptor-alpha (FXR/RXRa) is the master transcriptional regulator of bile salt
synthesis and transport in liver and intestine. FXR is activated by bile acids, RXRa by the vitamin A–derivative 9-cis retinoic
acid (9cRA). Remarkably, 9cRA inhibits binding of FXR/RXRa to its response element, an inverted repeat-1 (IR-1). Still, most
FXR/RXRa target genes are maximally expressed in the presence of both ligands, including the small heterodimer partner
(SHP). Here, we revisited the FXR/RXRa-mediated regulation of human SHP.
Methods: A 579-bp hSHP promoter element was analyzed to locate FXR/chenodeoxycholic acid (CDCA)- and RXRa/9cRA-
responsive elements. hSHP promoter constructs were analyzed in FXR/RXRa-transfected DLD-1, HEK293 and HepG2 cells
exposed to CDCA, GW4064 (synthetic FXR ligand) and/or 9cRA. FXR-DNA interactions were analyzed by in vitro pull down
assays.
Results: hSHP promoter elements lacking the previously identified IR-1 (2291/2279) largely maintained their activation by
FXR/CDCA, but were unresponsive to 9cRA. FXR-mediated activation of the hSHP promoter was primarily dependent on the
2122/269 region. Pull down assays revealed a direct binding of FXR to the 2122/269 sequence, which was abrogated by
site-specific mutations in a binding site for the liver receptor homolog-1 (LRH-1) at 278/270. These mutations strongly
impaired the FXR/CDCA-mediated activation, even in the context of a hSHP promoter containing the IR-1. LRH-1 did not
increase FXR/RXRa-mediated activation of hSHP promoter activity.
Conclusion: FXR/CDCA-activated expression of SHP is primarily mediated through direct binding to an LRH-1 binding site,
which is not modulated by LRH-1 and unresponsive to 9cRA. 9cRA-induced expression of SHP requires the IR-1 that overlaps
with a direct repeat-2 (DR-2) and DR-4. This establishes for the first time a co-stimulatory, but independent, action of FXR
and RXRa agonists.
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Introduction
The farnesoid X receptor (FXR/NR1H4) and the liver receptor
homolog-1 (LRH-1/NR5A2) are central factors in the control of
bile salt homeostasis. In the liver, LRH-1 regulates expression of
cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting
enzyme in bile salt synthesis, as well as the bile salt export pump
(BSEP/ABCB11) the major hepatobiliary bile salt exporter [1,2].
FXR typically acts together with the retinoid X receptor-alpha
(RXRa/NR2B1) and upon activation by bile salts induces the
expression of BSEP [3,4] and the small heterodimer partner
(SHP/NR0B2) [5–7]. SHP, in turn, binds to LRH-1 and thereby
inhibits the expression of CYP7A1 [6]. In a similar way, SHP may
bind RXRa/retinoic acid receptor (RAR) and thereby also repress
expression of the hepatic bile salt importer (the Na+-taurocholate
cotransporting polypeptide; NTCP/SLC10A1) [8]. SHP-depen-
dent repression of bile salt synthesis acts in parallel with fibroblast
growth factor 19 (FGF19)-mediated repression, which may
originate either from FXR-induced expression in the intestine (in
rodents) [9] or the liver (particular in humans) [10].
Both LRH-1 and FXR belong to the superfamily of nuclear
receptors. FXR/RXRa binds to an inverted repeat sequence
spaced by 1 nucleotide (IR-1) conforming to the consensus G/
AGGTCAnTGACCT [11]. Acting as a monomer, the conserved
DNA binding site of LRH-1 is currently defined as (c/tCAAGGc/
tCg/a) [12,13]. In recent mouse whole-genome chromatin-
immunoprecipitation (ChIP) experiments a remarkable enrich-
ment of LRH-1-type binding sites was detected in DNA sequences
precipitated with antibodies against FXR. FXR and LRH-1 were
found to synergistically induce transcription of mouse Shp [14]. In
line with these observations, functional LRH-1 binding sites have
been identified in several genes that are also controlled by FXR/
RXRa including BSEP [2], SHP [6], organic solute transporter
alpha/beta (OSTa/b) [15] and fatty acid synthase (FAS) [16,17].
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FXR/RXRa-mediated transcriptional control is primarily
regulated by their ligands, bile acids (in particular chenodeoxy-
cholic acid (CDCA)) and 9-cis retinoic acid (9cRA), respectively.
Earlier, we and others have shown that these ligands have opposite
effects on binding of FXR/RXRa to the IR-1 and the resulting
transcriptional activity of the human BSEP promoter [18,19].
FXR ligands (both CDCA and GW4064) strongly increase FXR/
RXRa-mediated expression of BSEP, while co-administration of
9cRA effectively represses this effect. 9cRA strongly reduced the
binding of FXR/RXRa to the IR-1 sequences as they are present
in the human BSEP and SHP promoters. In contrast to the effect
on BSEP expression, however, CDCA and 9cRA synergistically
activate SHP transcription, in both in vivo and in vitro experiments
[19]. This suggests that the mechanisms by which these ligands
control FXR/RXRa-mediated regulation of BSEP and SHP may
be fundamentally different, while they are both considered to be
‘‘typical’’ FXR/RXRa target genes. Opposite effects of RXRa
ligands on CDCA-induced expression of FXR/RXRa target
genes have been described by others also [18,20], but the
differential mechanisms remain elusive so far.
Over the last decade it has become evident that the function of
FXR and SHP is not restricted to bile acid synthesis, but that these
factors also play a role in liver regeneration, viral replication,
tumor suppression, fibrogenesis, glucose and lipid metabolism
[21,22]. It is therefore highly relevant to understand the molecular
mechanisms that determine the ligand-selective regulation of
FXR/RXRa target genes, in particular that of SHP.
Materials and Methods
Cell lines and culture conditions
DLD-1 (ATCCH CCL221TM) and HepG2.rNtcp [23] cells were
cultured in Dulbecco’s modified Eagle medium (DMEM) or RPMI
1640 supplemented with lipid-stripped serum (Biosera, East
Sussex, UK) as described previously [19,24]. HEK293 cells
(ATCCH CRL1573TM) were cultured like HepG2 cells. Culture
conditions for mRNA and luciferase reporter assays were
described before [19]. Cells were exposed to 100 mmol/L CDCA
(Calbiochem-Novabiochem, San Diego, CA, USA) or 1 mmol/L
GW4064 (Tocris, Ellisville, USA) and/or 1 mmol/L 9cRA (Sigma
Aldrich, St. Louis, MO), as described in the text. A DLD-1 cell line
over-expressing hFXR (DLD-1.hFXR) was generated by stable
transfection of pcDNA3-hFXR in DLD-1.
Transfection
HepG2.rNtcp and HEK293 cells were transfected as described
previously [4]. DLD-1 cells were transfected using Transfectine
(Biorad, Hercules, CA) at a ratio of 3 ml Transfectine per mg DNA
as recommended by the manufacturer. Expression plasmids of
hFXR (pcDNA3-hFXR) and hRXRa (pSG5-hRXRa) were used
at 200 ng and 100 ng, respectively, and luciferase reporter
plasmids (pGL3-basic derivatives) at 1 mg per 9.6 cm2 well. If
needed, total amount of DNA was adjusted with pCMV5 plasmid
to 1.3 mg per well.
Plasmids
The 579-bp (569/+10) hSHP promoter construct in pGL3 basic
was a kind gift from Dr. S.M. Houten (Academic Hospital
Amsterdam, The Netherlands). pcDNA5-mLrh-1 was a kind gift
from Dr. J. Hageman (University Medical Center Groningen, The
Netherlands) [25]. The plasmids pcDNA3-hFXR, pSG5-hRXRa,
pCMV5 and details about their use have been described [4,19].
Site-directed mutagenesis
59-truncated mutants of the hSHP promoter were made by PCR
from the pGL3 hSHP 2569/+10. pGL3 SHP 2569/+10 FXRE
KO [6] was generated via site-directed mutagenesis by full vector
amplification. Deletion mutants lacking intra promoter regions,
FXRE nonsense mutants and half-site nonsense mutants were
generated by amplifying the two individual promoter fragments
flanking the region to be mutated or deleted. Subsequently, these
two fragments were fused by overlap PCR. PCR products were
KpnI/BglII-ligated into pGL3 basic (Promega, Madison, USA).
Oligo’s (Invitrogen, Paisley, UK) used to generate these SHP
promoter mutants are shown in Table S1. Endotoxin-free
plasmids were isolated (Macherey-Nagel, Du¨ren, Germany) from
E. coli Top10 cells (Invitrogen, Paisley, UK). All promoter
constructs were sequenced (BaseClear; Leiden; The Netherlands)
to assure that the correct mutations were introduced.
mRNA isolation and Q-PCR
mRNA was isolated from DLD-1, HepG2.rNtcp and HEK293
cells. RT-QPCR was performed as was described before [26].
Sequences of the primer/probe sets are shown in Table S2.
Luciferase reporter assays
Cells were lysed in 500 ml passive lysis buffer (Promega,
Madison, USA). After centrifugation, 20 ml of the supernatant
was used to determine luciferase activity in a MPL1 Microplate
Luminometer (Berthold Detection Systems). Using 50 ml luciferase
substrate (Promega, Madison, USA), delay time set to 2.05 seconds
and measuring time set to 10 seconds.
FXR Pull-Down Assay
A FXR pull down assay was performed as described before [19]
on a nuclear extract of DLD-1 cells that stably expressed hFXR
(DLD-1.hFXR), treated for 24 hours with CDCA. 68-bp biotin-
labeled DNA probes containing the ‘‘wild type’’ 2122/269
(GGGGCAATGTCTGTGTGTTTTTTTCAATGAACATGAC-
TTCTGGAGTCAAGGTTGTTGGGCCATTCCCC; the putative
LRH-1 binding site is indicated in ‘‘italics’’) and ‘‘mutated’’ -122/2
69 (GGGGCAATGTCTGTGTGTTTTTTTCAATGAACAT-
GACTTCTGGAGTCATTAATTTTGGGCCATTCCCC; the
mutated positions within the putative LRH-1 binding site are
underlined) region were used to precipitate FXR. Biotin-labeled
DNA probes containing a fragment of the BSEP promoter including
the IR-1 (TGTCACTGAACTGTGCTTGGGCTGCCCTTAGG-
GACATTGATCCTTAGGCAAAT; the IR-1 is indicated in italics) or
a fragment of the LacI promoter (GTAGTGGCGAAATTGT-
GAGCGCTCACAATTCGTTTGGCCG) were used as positive
and negative controls, respectively. Nuclear extracts were pre-
incubated (1 h at 4uC) with 3-fold excess of unlabeled ‘‘wild type’’2
122/254, ‘‘mutated’’ 2122/254, BSEP-IR-1 (CCCTTAGGGA-
CATTGATCCTTAGG; the IR-1 is indicated in italics) or LacI DNA
probes in competition experiments. FXR binding was analyzed by
western blotting, using anti-FXR (PP-A9033A-00; Perseus, Japan),
exposed in a ChemiDoc XRS system and quantified using the
Quantity One software package (Bio-Rad, GmbH, Munich,
Germany).
Statistical analysis
Data are presented as means 6 sd. Differences between
conditions were determined in SPSS by Kruskal-Wallis followed
by pair-wise comparison of groups by Mann-Whitney U with p#
0.05.
hFXR-Mediated hSHP Expression Is IR-1 Independent
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Results
The IR-1 at 2291/2279 is largely dispensable for FXR-
dependent induction of the human SHP promoter
The RXRa ligand 9cRA lowers BSEP expression by inhibiting
FXR/RXRa binding to the IR-1 [18,19], while transcription of
other FXR/RXRa target genes (SHP, OSTb, ileal bile acid
binding protein (IBABP), FGF19; see Figure S1) is super-induced.
Here, we performed a detailed analysis of the human SHP
promoter to obtain insight in the molecular mechanisms by which
bile acids and 9cRA synergistically induce transcription of FXR/
RXRa target genes. The -569/+10 SHP promoter element
described earlier [6] showed the same pattern of regulation by
CDCA and 9cRA as observed for genomic SHP (Figure 1 and
Figure S1). CDCA treatment resulted in a 12-fold increase of the
SHP promoter activity and this was super-induced by 9cRA (+45%
to 17-fold induction compared to untreated cells). An FXRE/IR-1
was previously identified at position 2291/2279 in the SHP
promoter [5–7]. As expected, a 59-truncated SHP promoter
element up to position 2303 (2303/+10) retained the CDCA-
induction (9.8-fold) and 9cRA super-induction (+43% to 14-fold)
characteristics. Further 59 shortening of the SHP promoter element
Figure 1. The IR-1 at2291/2279 is required for 9cRA-, but not for CDCA-mediated induction of the human SHP promoter. DLD-1 cells
were transfected with hFXR and hRXRa expression plasmids and various hSHP promoter constructs as indicated. Cells were treated with or without
100 mmol/L CDCA and/or 1 mmol/L 9cRA. The synergistic effect of the FXR ligand (CDCA) and RXRa ligand (9cRA) on SHP promoter activity depends
on the previously identified IR-1 located at 2291/2279. Mutation or deletion of this IR-1 sequence did not abolish SHP promoter activation by FXR/
CDCA. Luciferase activity was measured to determine the SHP promoter activity. Data are presented as means 6 SD; n$3. Vehicle-treated conditions
are set to 1. p#0.05 for *) in a pairwise comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0088011.g001
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to 2278/+10 (deleting the IR-1) led to the loss of 9cRA super-
induction. Remarkably, the CDCA-induction of the 2278/+10
SHP promoter element remained intact (8.1-fold; Figure 1).
Disrupting the IR-1 sequence in the 2303/+10 promoter element
(by an IR-1 knock out mutation (KO) [6], replacement by a
nonsense sequence (NS) or full deletion (DEL)) led to the absence
of 9cRA super-induction, but maintained the CDCA-induction
(Figure 1), even in the context of the larger 2569/+10 SHP
promoter element (Figure S2). These data indicate that the
9cRA-mediated activation of the human SHP promoter depends
on the IR-1 sequence at position 291/2279. However, this
sequence is (largely) dispensable for the CDCA-induced activity.
This latter finding was highly surprising and prompted us to study
this in further detail.
CDCA-induced activation of the 2278/+10 SHP promoter
elements depends on FXR
The CDCA-induced activation of the2278/+10 SHP promoter
element was comparable to the 2303/+10 SHP element (8.1-fold
vs. 9.8-fold, respectively) and was fully dependent on the presence
of FXR (Figure 2). The FXR/CDCA-induction was lost when
the SHP promoter was reduced to a minimal element of269/+10.
This indicates that the 2278/269 region in the human SHP
promoter contains a yet unidentified sequence that is essential for
FXR/CDCA-dependent regulation.
The novel FXR/CDCA-responsive element is located in
the 2122/269 region of the SHP promoter
Two fragments (2203/2122 or 2122/269) were deleted from
the 2303/+10 and the 2278/+10 SHP promoter elements to
delineate the region involved in the regulation by FXR/RXRa/
CDCA (Figure 3A). Deletion of the 2122/269 fragment from
the 2278/+10 SHP promoter element made it unresponsive to
FXR/RXRa/CDCA, while deletion of the 2203/2122 did not
reduce the FXR/RXRa/CDCA-activation. Importantly, the 2
122/269 deletion also strongly reduced the FXR/RXRa/
CDCA-activation of the IR-1-containing 2303/+10 SHP pro-
moter element (Figure 3B). Similar results were obtained when
FXR/RXRa-transfected cells were treated with the synthetic
FXR ligand GW4064 instead of CDCA (Figure 3C). The FXR/
RXRa/CDCA- and FXR/RXRa/GW4064-induced regulation
of the SHP promoter fragments was most pronounced in intestinal
DLD-1 cells, but was also observed in hepatic HepG2.rNtcp and
renal HEK293 cells (Figure 4). These data indicate that the 2
122/269 sequence is crucial for FXR-dependent regulation of the
SHP promoter. The previously identified IR-1 at position 2
291/2279 contributes only to a minor extend to the FXR-
dependent regulation of SHP.
An LRH-1 site is required for the FXR-dependent
induction of human SHP
The 2122/269 region from the SHP promoter was screened
for putative nuclear receptor binding sites. An IR-1-like sequence
is detected at2118/2106 (AtGTCtgTGtgtT) with 7 out of 12 IR-
1 consensus nucleotides. Alternatively, FXR-regulation may act
through a previously identified DR-1/PPARc binding site at
position 290/278 [27] as it also contains the core TGACCT
sequence. In addition, this region contains a binding site for LRH-
1 (TCAAGGTTG at 279/271). Site-directed mutations were
introduced in these 3 regions. While mutations in the IR-1-like
and DR-1 sites only slightly reduced FXR-mediated induction of
SHP promoter activity, it was almost completely abrogated when
the LRH-1 site was mutated (Figure 5). Previously, it was
suggested that FXR and LRH-1 may synergistically induce
expression of murine Shp [14]. While the human SHP promoter
activity was dose-dependently induced by co-expression of
mLRH-1, confirming the presence of a functional LRH-1 site, it
did not enhance the FXR/CDCA-induced activity of the SHP
promoter (Figure 6). In fact, at high doses, LRH-1 rather
represses FXR/CDCA-activation of the 2303/+10 hSHP pro-
moter element. Similar results were obtained for the 2569/+10
hSHP promoter (Figure S3). In addition, CDCA treatment of
FXR/RXRa-transfected DLD-1 cells did not induce LRH-1
expression (Figure S4). Collectively, these data indicate that the
FXR-mediated induction of human SHP is independent of LRH-
1, but requires the LRH-1 binding site.
FXR physically binds to the LRH-1 site in the 2122/269
region of the human SHP promoter
Next, we analyzed whether FXR binds directly to the 2122/2
69 region in the human SHP promoter by applying an FXR-pull
down assay [19] using a biotin-labeled 68-bp DNA fragment
containing the 2122/269 region of the SHP promoter. This SHP
promoter fragment efficiently precipitated FXR from nuclear
extracts of CDCA-treated DLD-1 cells that stably overexpress
hFXR (DLD-1.hFXR), similar as the positive control (BSEP-IR-1)
Figure 2. FXR is required for CDCA-induced activation of the2278/+10 SHP promoter. DLD-1 cells were transfected with hFXR and hRXRa
expression plasmids and various hSHP promoter constructs as indicated. Cells were treated with or without 100 mmol/L CDCA. Luciferase activity was
measured to determine the SHP promoter activity. Data are presented as means6 SD; n$3. P#0.05 for *) in a pairwise comparison by Mann-Whitney
U test.
doi:10.1371/journal.pone.0088011.g002
hFXR-Mediated hSHP Expression Is IR-1 Independent
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did (Figure 7A). Binding of FXR was abrogated when the LRH-1
site was mutated in the 2122/269 element. Moreover, the
mutated sequence did not compete for FXR binding, while the
wild type 2122/269 SHP promoter fragment did (Figure 7A
and B). Taken together, these data show that FXR-mediated
expression of human SHP is largely controlled via direct binding
of FXR to a newly-identified DNA sequence that includes an
LRH-1 binding site at position 279/271.
Discussion
In this study, we show that FXR regulates human SHP
expression primarily via direct binding to an LRH-1 site and not
the previously identified IR-1. No synergism was detected between
FXR and LRH-1 in regulation of human SHP. In contrast, the IR-
1 sequence was required for 9cRA-induced expression of SHP.
This is the first in-depth analysis of the co-stimulatory transcrip-
tional regulation by the ligands of FXR and RXRa, CDCA and
Figure 3. A FXR/RXRa/CDCA-responsive element is located in the 2122/269 region of the SHP promoter. A) shows an overview of the
different constructs used to localize the FXR-responsive element in the 2278/269 region of the SHP promoter. Relevant binding sites for other NRs
are included. (B, C) DLD-1 cells were transfected with the indicated hSHP promoter constructs and expression plasmids for hFXR and hRXRa. Cells
were treated with or without 100 mmol/L CDCA (B) or 1 mmol/L GW4064 (C). Luciferase activity was measured to determine SHP promoter activity.
Data are presented as means of 6 SD; n$3. Significant differences are indicated when compared to CDCA/GW4064-treated 2569/+10 (a); CDCA/
GW4064-treated 2303/+10 (b); CDCA/GW4064-treated 2278/+10(c). P#0.05 in a pairwise comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0088011.g003
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9cRA. This mechanism is fundamentally different from FXR/
RXRa-mediated regulation of BSEP that acts through an IR-1
[4].
Sequencing of DNA fragments that bind FXR in the mouse
genome has recently revealed that indeed the IR-1 is the most
prominent binding site of this transcription factor [14,28,29].
Notably, the IR-1 in the mouse, rat and human SHP promoters
deviate from the experimentally established IR-1 consensus at least
at one crucial position (GAGTTAaTGACCT, where the under-
lined T in the SHP IR-1 is a G or C in the consensus IR-1). The
second most enriched FXR-binding sequence in the genome-wide
chromatin immunoprecipitation experiments appeared to confirm
to an LRH-1 binding site that is in close proximity to the IR-1
[14]. Co-transfection experiments revealed a synergistic effect of
FXR/RXRa and LRH-1 on the activity of the Shp promoter.
Our data show that 1) FXR-mediated expression of human
SHP is largely independent of the IR-1, 2) LRH-1 does not
enhance FXR/RXRa-induced SHP promoter activity, 3) FXR is
precipitated with a DNA fragment containing the LRH-1 site,
which is abrogated when this site is mutated; 4) FXR-mediated
induction of a SHP promoter lacking an IR-1 is similar in cells
without endogenous LRH-1 (HEK293) and in cells that contain
intermediate (DLD-1) or high levels of LRH-1 (HepG2.rNtcp).
This suggest that FXR-mediated regulation does not depend on
the presence of LRH-1, which is in line with the observation that
GW4064-induced Shp mRNA expression in mouse liver was
hardly affected by the absence of Lrh-1 [30].
Most surprising was the fact that the IR-1 was extraneous for
FXR-mediated induction of the hSHP promoter, but required a
downstream sequence than harbors a LRH-1 binding site. The
minimal LRH-1 binding site was, however, not sufficient to bind
significant amounts of FXR in pull-down assays (Figure S5),
suggesting that sequences flanking the LRH-1 binding site are
required for efficient FXR binding. This is corroborated by the
observation that mutations in the 2122/269 region outside the
LRH-1 consensus sequence also reduced the FXR-induced SHP
promoter activity, though this was less pronounced than the
mutations in the LRH-1 site. Taken together, we conclude that the
LRH-1 site in the human SHP promoter is most important site for
FXR-mediated expression. Importantly, this novel FXR binding
site is fully conserved in the human, mouse and rat SHP promoters
(Figure S6).
Another remarkable finding was that the previously identified
IR-1 was actually required for 9cRA-induced expression of SHP.
Previously, it has been shown that the IR-1 overlaps with an
LXRa/RXRa DR-4 response element at 2284/2269 [31]. The
synthetic ligand RXRa was shown to be a potent activator of liver
X receptor-alpha (LXRa)/RXRa-induced transcriptional activity,
even more so than the LXRa ligand T0901317. Thus, it is very
well possible that 9cRA induces SHP expression through LXRa/
RXRa. In addition, the IR-1 also contains a putative DR-2
sequence (Figure S7). RXRa homodimers and RXRa/RAR
heterodimers have been shown to bind DR-2 elements [32]. SHP
promoter activity was indeed induced by 9cRA-activated RXRa,
which was not affected by co-transfection with RAR (data not
shown). So, alternatively, 9cRA may act via RXRa homodimers
by binding the DR-2 in the 2291/2279 region in the SHP
promoter.
At present it is unknown how common this alternative pathway
of FXR-mediated transcription through LRH-1(-like) sequences is.
The FXR/CDCA-induced activity via the LRH-1 site is
insensitive to 9cRA. Together with the fact that the ‘‘IR-1’’ is
required for the 9cRA-mediated induction of SHP provides the
first molecular mechanism explaining how these ligands (9cRA
and CDCA) lead to maximum induction of transcription, albeit
via two independent sites. Maximum expression after exposure to
both ligands was also observed for OSTb, IBABP, FGF19 and
others observed this for phospholipid transfer protein (PLTP) [33]
and SULT2A1: sulfotransferase 2A1 (SULT2A1/STD) [34]. In
contrast, OSTa showed a BSEP-like pattern (9cRA blocks CDCA-
induced expression). Since 9cRA was found to reduce binding of
FXR/RXRa to the IR-1 sequence (as present in the human BSEP
and SHP promoter), the IR-1 containing promoters of OSTb,
IBABP and FGF19 need to harbor compensatory mechanism that
ultimately lead to maximal transcription with both ligands.
Figure 4. The 2122/269 region is required for optimal FXR-ligand-mediated induction of the SHP promoter in DLD-1, HEK293 and
HepG2 cells. The colon carcinoma (DLD-1), human embryonic kidney (HEK293) and hepatoma (HepG2.rNtcp) cell lines were transfected with the
indicated hSHP promoter constructs and expression plasmids for hFXR and hRXRa. Cells were treated with or without 100 mmol/L CDCA (A) or
1 mmol/L GW4064 (B). Luciferase activity was measured to determine SHP promoter activity. Data are presented as means of 6 SD; n$3. Promoter
activity in CDCA/GW4064-treated condition is significantly different from the 2278/+10 construct in DLD-1 (a), HEK293 (b) or HepG2.rNtcp (c) cells.
P#0.05 in a pairwise comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0088011.g004
hFXR-Mediated hSHP Expression Is IR-1 Independent
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Figure 5. The LRH-1 site is required for FXR-induced expression of SHP. (A) shows the location of IR-1-like half sites and an LRH-1 site in the
2122/269 region of the hSHP promoter. The latter was previously identified in the murine Shp promoter [35] and conserved in rat and human (see
Figure S6). All 4 IR-1-like sites and the LRH-1 site were mutated and analyzed for the effect on FXR/CDCA-mediated induction of the2278/+10 hSHP
promoter (B) mutating one of the IR-1 half-sites did not or only partially reduce FXR/CDCA-dependent activation of the 2122/269 hSHP promoter
fragment, whereas mutations in the LRH-1 site strongly reduced the response of the 2122/269 hSHP promoter fragment to FXR/CDCA-stimulation.
*) significantly different from CDCA treated 278/+10 WT (C) in the context of the 2569/210 hSHP promoter fragment the LRH-1 site is the dominant
FXR/CDCA response element (over the previously identified IR-1). DLD-1 cells were transfected with hFXR and hRXRa expression plasmids and various
hSHP promoter constructs as indicated. Cells were treated with or without 100 mmol/L CDCA. Luciferase activity was measured to determine the SHP
promoter activity. a) significantly different from CDCA treated 569/+10 WT. b) significantly different from CDCA treated 2569/+10 IR-1 KO. Data
presented as means 6 SD; n$3. P#0.05 for *), a) and b) in a pairwise comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0088011.g005
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Figure 6. No synergy between FXR and LRH-1 in human SHP regulation. LRH-1 dose-dependently induced activation of the 2303/+10 hSHP
promoter fragment, confirming the presence of a functional LRH-1. In the presence of FXR a similar dose response curve is observed. However, in the
presence of CDCA, FXR and LRH-1 do not synergistically activate the SHP promoter. LRH-1 rather limits the FXR/CDCA-dependent activation at a
higher dose. DLD-1 cells were transfected with hFXR and hRXRa expression plasmids, the 2303/+10 hSHP promoter construct and/or increasing
amounts of an mLrh-1 expression plasmid as indicated. Cells were treated with or without 100 mmol/L CDCA. Luciferase activity was measured to
determine the SHP promoter activity. a) significantly different from 0 ng mLrh-1 vehicle, between vehicle treated conditions. b) significantly different
from 0 ng mLrh-1 FXR/RXRa, between FXR/RXRa treated conditions. Data presented as means 6 SD; n$3. P#0.05 for a) and b) in a pairwise
comparison by Mann-Whitney U test.
doi:10.1371/journal.pone.0088011.g006
Figure 7. FXR binds to the LRH-1 responsive element in the hSHP promoter. FXR was precipitated from nuclear extracts of hFXR-
overexpressing DLD-1 cells using a DNA probe containing the SHP 2122/269 region (‘‘wild type’’(WT) or ‘‘mutated’’(mut)), the IR-1 from the hBSEP
promoter (positive control), the LacI binding site (negative control) or empty beads (EB, negative control). A) DNA probes of SHP 2122/269 and
BSEP-IR-1 bind FXR. Competition experiments were performed with 3-fold excess hBSEP-IR-1 or LacI lacking a biotin label. B) the SHP 2122/269
region with a mutated LRH-1 site failed to precipitate or compete for FXR binding. Competition experiments were performed with 3-fold excess wild
type SHP 2122/269, mutated SHP 2122/269 or LacI lacking a biotin label.
doi:10.1371/journal.pone.0088011.g007
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Our data contrast to those previously reported by Lu et al. [5]
and Goodwin et al. [6], who reported that the IR-1 is essential for
FXR-induced expression of human SHP. We followed the same
experimental approach as these studies. Most of our data was
generated using DLD-1 cells, in which we observed the most
robust FXR-mediated induction of the SHP promoter. Still, we
show that the IR-1 was also dispensable for FXR-mediated
induction of the SHP promoter in HEK293 and HepG2 cells,
which were used in the earlier studies. A putative explanation for
these, seemingly opposite, observations may be that both the IR-1
and the LRH-1 site can bind FXR and activate SHP expression,
but that their relative contribution may depend on the cellular
and/or nuclear levels of FXR, RXRa and their ligands. These
factors may vary between cell types, passage numbers and the
experimental conditions in these 3 studies. The RXRa ligand
(9cRA) may reduce the binding of the FXR/RXRa heterodimer
to the IR-1 sequence and stimulate LXRa/RXRa or RXRa
homodimer binding in the 2291/2269 region. In contrast, 9cRA
does not affect the FXR-mediated regulation of SHP via the 2
122/269 element. Physiologically, this maintains SHP-mediated
regulation of bile salt synthesis (CYP7A) and bile salt import
(NTCP, ASBT) independent of the vitamin A/9cRA levels. In line
with this, bile salt-mediated induction of Shp was maintained in
vitamin A-deficient mice [19].
In conclusion, our study reveals for the first time a molecular
mechanism of FXR-activated transcription that is not inhibited by
the RXRa ligand 9cRA, which is the most frequent mode of
regulation observed for FXR-target genes. Surprisingly, this is
mediated through a non-IR-1 FXR response element that shows
typical characteristics of an LRH-1 DNA binding consensus.
Supporting Information
Figure S1 Gene- and cell type-specific regulation of
FXR/RXRa target genes by 9cRA. HepG2.rNtcp (A) and
DLD-1 (B) cells were transfected with expression plasmids for
hFXR and hRXRa and treated with or without 100 mmol/L
CDCA and/or 1 mmol/L 9cRA. mRNA levels of FXR target
genes were determined by Q-PCR. Data are corrected for 18S and
displayed as means 6 SD; n$3. CDCA-treated conditions are set
to 100. Significant differences (P#0.05) are indicated when
compared to untreated condition (a), 9cRA-treated condition (b),
CDCA-treated condition (c) or CDCA/9cRA-treated condition (d)
in a pair-wise comparison by Mann-Whitney U test.
(TIF)
Figure S2 Inactivation of the IR-1 at position2291/2279
does not abolish FXR/CDCA-mediated induction of the
2569/+10 hSHP promoter. DLD-1 cells were transfected with
hFXR and hRXRa expression plasmids and the 2569/+10 SHP
promoter construct (B). Cells were treated with or without
100 mmol/L CDCA and/or 1 mmol/L 9cRA. Luciferase activity
was measured to determine the SHP promoter activity (A). Data
presented as means6 SD; n$3. Vehicle-treated conditions are set to
1. P#0.05 for *) in a pair-wise comparison byMann-WhitneyU test.
(TIF)
Figure S3 No synergy between FXR and LRH-1 in
human SHP regulation. LRH-1 dose dependently induced
activation of the 2569/+10 hSHP promoter fragment, confirming
the presence of a functional LRH-1. In the presence of FXR a
similar dose response curve is observed. However, in the presence
of CDCA, FXR and LRH-1 do not synergistically activate the
SHP promoter. LRH-1 rather limits the FXR/CDCA-dependent
activation at a higher dose.DLD-1 cells were transfected with
hFXR and hRXRa expression plasmids, the 2569/+10 SHP
promoter construct and/or increasing amounts of the mLrh-1
expression plasmid as indicated. Cells were treated with or without
100 mmol/L CDCA. Luciferase activity was measured to deter-
mine the SHP promoter activity. Data presented as means 6 SD.
(TIF)
Figure S4 FXR does not induce LRH-1 expression in
DLD-1 cells. DLD-1 cells were transfected with expression
plasmids for hFXR and hRXRa and treated with or without
100 mmol/L CDCA. mRNA levels of LRH-1 were determined byQ-
PCR. Data are corrected for 18S and displayed as means6 SD; n$3.
(TIF)
Figure S5 FXR does not interact with the minimal LRH-
1 responsive element in the hSHP promoter. FXR was
precipitated from nuclear extracts of hFXR-overexpressing DLD-
1 cells using a DNA probe containing the 289/265 region of the
human SHP promoter (ACTTCTGGAGTCAAGGTTGTT-
GGGC) including the LRH1-RE (underlined), an 53-bp fragment
of the BSEP promoter containing the IR-1 or a LacI probe.
Competition experiments were performed with 3-fold excess IR-1
or LacI probe lacking a biotin label.
(TIF)
Figure S6 Comparison of human, mouse and rat SHP
promoter sequences. The IR-1 (italics+bold) is not fully
conserved, whereas the LRH-1 binding site (underlined) is fully
conserved in the mouse, rat and human SHP promoter.
(TIF)
Figure S7 The 9cRA responsive element accommodates
an IR-1, an DR-4 and a putative DR-2. The IR-1 (2291/2
279) overlaps with a previously identified DR-4 (Goodwin et al.,
2003; binds LXRa/RXRa) and a putative DR-2 (binds RXRa/
RXRa) and RXRa/RAR).
(TIF)
Table S1 Oligo’s used to create mutant constructs of
the hSHP 2569/+10 promoter.
(TIF)
Table S2 Taqman primer-probe sets used for QPCR.
Probes were FAM TAMRA labeled.
(TIF)
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